Renin substrate in granules from rat kidney cortex

Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA

We recently reported that urinary excretion rates of angiotensinogen provide a specific index of the intrarenal renin-angiotensin system status in angiotensin II-dependent hypertensive rats. Angiotensinogen concentrations in mouse plasma are thought to be much lower than those in rat plasma; however, detailed information is deficient due to lack of direct quantitative measurements of rodent angiotensinogen. To elucidate this issue, we have developed a quantitative method for measurement of rodent angiotensinogen using a sandwich-type ELISA. The standard curve for mouse and rat angiotensinogen exhibited a high linearity at 0.16-10 and 0.08-5 ng/ml, respectively, with correlation coefficients >0.99. While plasma angiotensinogen concentrations of male high serum IgA (HIGA) mice (IgA nephritis model animals, 1,308 +/- 47 ng/ml; n = 10) were lower than those of control BALB/c mice (1,620 +/- 384; n = 12), urinary angiotensinogen concentrations of HIGA mice (14.6 +/- 1.5 ng/ml; n = 34) were higher than those of BALB/c mice (4.6 +/- 0.1; n = 2). In a similar manner, while plasma angiotensinogen concentrations of Zucker diabetic fatty (ZDF) obese rats (type 2 diabetic model animals, 1,789 +/- 50 ng/ml; n = 5) were lower than those of control ZDF lean rats (2,296 +/- 47; n = 5), urinary angiotensinogen concentrations of ZDF obese rats (88.2 +/- 11.4 ng/ml; n = 15) were higher than those of ZDF lean rats (31.3 +/- 1.9; n = 15). These data indicate that plasma and urinary angiotensinogen concentrations are less in mice than rats. However, these data suggest that urinary angiotensinogen levels are different from plasma angiotensinogen levels in rodents. The development of rodent angiotensinogen ELISA allows quantitative comparisons in mouse and rat angiotensinogen levels in models of hypertension and cardiovascular and kidney diseases.

Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials

AIM

The aim of this study was to determine the role of tissue angiotensin-converting enzyme (ACE) inhibitors in the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure in randomized placebo-controlled clinical trials using pooled meta-analysis techniques.

METHODS

Randomized placebo-controlled clinical trials of at least 12 months duration in patients with diabetes mellitus without left ventricular systolic dysfunction or heart failure who had experienced a prior cardiovascular event or were at high cardiovascular risk were selected. A total of 10 328 patients (43 517 patient-years) from four selected trials were used for meta-analysis. Relative risk estimations were made using data pooled from the selected trials and statistical significance was determined using the Chi-squared test (two-sided alpha error <0.05). The number of patients needed to treat was also calculated.

RESULTS

Tissue ACE inhibitors significantly reduced the risk of cardiovascular mortality by 14.9% (p = 0.022), myocardial infarction by 20.8% (p = 0.002) and the need for invasive coronary revascularization by 14% (p = 0.015) when compared to placebo. The risk of all-cause mortality also tended to be lower among patients randomized to tissue ACE inhibitors, whereas the risks of stroke and hospitalization for heart failure were not significantly affected. Treating about 65 patients with tissue ACE inhibitors for about 4.2 years would prevent one myocardial infarction, whereas treating about 85 patients would prevent one cardiovascular death.

CONCLUSION

Pooled meta-analysis of randomized placebo-controlled trials suggests that tissue ACE inhibitors modestly reduce the risk of myocardial infarction and cardiovascular death and tend to reduce overall mortality in diabetic patients without left ventricular systolic dysfunction or heart failure.

Renin: from 'pro' to promoter

Renin is the rate-limiting enzyme in a cascade that leads to production of angiotensin II, which is perhaps our most important regulator of salt and water balance and blood pressure. In this personal perspective, I describe how I entered the renin field 33 years ago by discovering that proteases increased the level of renin activity in biological fluids, so revealing the existence of a 'pro' form of the molecule. This led me on a journey that encapsulated all of the major milestones in molecular discovery for renin. These included (1) the elucidation of the steps in renin biosynthesis, (2) the cloning of renin cDNA and its gene, (3) demonstration of the structure of the renin protein, (4) using the renin gene in the first genetic studies in hypertension, (5) finding the mechanism by which the major controller, cyclic AMP, regulates the promoter, (6) showing that a strong enhancer and its weak promoter control this physiologically regulatable gene in accord with the variegation (on/off switching) model, and (7) being the first to identify molecules involved in posttranscriptional control. The renin molecule, its gene and molecular control are now very well understood, but more fine details on the topic of renin continue to emerge to delight 'reninologists' and others.

Association analyses of NsiI RFLP of human insulin receptor gene in hypertensives

Plasma angiotensinogen is elevated in essential hypertensives and shows a strong correlation with blood pressure. Patients with hypertension often display insulin resistance and we have found previously an association of a RsaI RFLP in intron 9 of the insulin receptor gene (INSR) with hypertension. Since insulin resistance is accompanied by hyperinsulinaemia and insulin can stimulate angiotensinogen production, we hypothesized that hypertension-associated genotypes of INSR may be associated with elevation in plasma angiotensinogen. We used PCR to detect a NsiI RFLP in exon 8 of INSR and examined its relationship with plasma angiotensinogen, as well as hypertension, in 134 Caucasian hypertensives with two hypertensive parents and in 126 normotensives. Plasma angiotensinogen tracked weakly with the major allele of the NsiI RFLP in hypertensives (p = 0.08). Moreover, the frequency of this allele was higher in lean hypertensives than in lean normotensives (p < 0.05) and in normolipidaemic hypertensives than normolipidaemic normotensives (p < 0.02). The present study thus suggests that there could be a relationship of plasma angiotensinogen with INSR genotype, and of each with hypertension.

Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II

The present study asks whether angiotensin II (ANG II), a potent inhibitor of renal renin synthesis and release, regulates renal angiotensinogen synthesis. ANG II (or vehicle) was intravenously infused into male Sprague-Dawley rats for 3 days (vehicle or 100, 300, and 1,000 ng.kg-1 x min-1, n = 8/group), significantly increasing mean plasma ANG II concentrations and raising mean arterial blood pressure (MAP). ANG II dose dependently suppressed plasma renin concentration, kidney renin concentration, and renal renin mRNA levels. In contrast, ANG II infusion increased renal angiotensinogen mRNA levels stepwise to 122, 136 (P < 0.05), and 150% (P < 0.05) of control and also increased both liver mRNA levels (P < 0.05) and plasma angiotensinogen concentration (P < 0.05). Three days of angiotensin-converting enzyme inhibition (10 mg.kg-1 x day-1 quinapril in drinking water, n = 8) significantly decreased MAP (P < 0.05) and increased both mean plasma renin concentration (P < 0.05) and renal renin mRNA levels (P < 0.005). Plasma ANG II concentration tended to decrease (not significant), and neither renal nor hepatic angiotensinogen mRNA levels displayed significant difference. However, when data from ANG II-infused and quinapril-treated rats were analyzed together, correlation between plasma ANG II concentrations and renal angiotensinogen mRNA levels was highly significant (P < 0.005, r = 0.585). Thus plasma ANG II upregulates renal angiotensinogen gene expression and downregulates renal renin gene expression, a reciprocal feedback regulation that may have important physiological consequences.

Production of angiotensinogen and renin-like activity by rabbit proximal tubular cells in culture

Recent studies suggest the presence of local angiotensin generating system in the kidney. By using in situ hybridization technique, mRNA for angiotensinogen has been shown to be present in the proximal tubule. In the present study, we have attempted to examine the production of angiotensinogen and renin-like activity by the proximal convoluted (PCT) and straight (PST) tubular cells. PCT and PST cells were obtained from microdissected rabbit proximal tubules and cultured in vitro. Angiotensinogen and renin-like activity were quantitated in culture media and cell lysates. It was found that PCT culture medium contained both angiotensinogen and renin-like activity, whereas only angiotensinogen was detected in PST culture medium. Support for de novo synthesis is provided by the observation that both angiotensinogen and renin-like activity in PCT culture medium increased in a time-dependent and hormone-sensitive manner in defined serum-free medium. These results thus demonstrate the actual production of angiotensinogen and renin-like activity by proximal tubular cells, and indicate that these locally synthesized components may contribute to the regulation of angiotensin generation in renal proximal tubule.

Intrarenal angiotensinogen: localization and regulation

Multiple lines of evidence (physiologic, immunohistochemical, and molecular biologic) support the presence of a complete intrarenal renin-angiotensin system (RAS). Localization of angiotensinogen messenger ribonucleic acid (mRNA) within the proximal tubule, together with demonstration of renin and converting enzyme mRNAs within the kidney, provide the most persuasive evidence for local, independent synthesis. Data from a combination of in situ hybridization studies, Northern analysis, and physiologic manipulations lead us to propose that a major site for action of a local RAS is the proximal tubule. There, locally generated angiotensins may regulate sodium reabsorption and urine pH. A variety of factors appear to regulate renal angiotensinogen. For instance sodium depletion increases the expression of renal angiotensinogen (as well as renin mRNA), as does high potassium intake and androgen administration. In pathologic states, such as experimental heart failure, and certain models of hypertension, such as the spontaneously hypertensive rat, expression of renal angiotensinogen mRNA levels is altered. It is proposed that changes in the intrarenal RAS may play a role in the maintenance of homeostasis and in the pathophysiology of various disease states.

Effect of an angiotensin-converting enzyme inhibitor on blood pressure and erythropoiesis in rats

Positive correlation between systolic blood pressure and plasma renin substrate was demonstrated in Wistar-Kyoto rats when plasma renin substrate was reduced to within a range of 18 and 88% of control values with varying amounts of ramipril. When ramipril was given in amounts that had a maximum effect on systolic blood pressure, marked changes in erythropoietin, reticulocyte count and hematocrit % were observed. Consistent blood pressure-lowering effect was evident for several weeks after ramipril withdrawal. Furthermore, blood pressure obtained 3 days after the rats were taken off ramipril correlated positively with the hematocrit % measured while the rats were still on ramipril (r = 0.83; P less than 0.001). Mean blood volume of 17 rats receiving ramipril was similar to that of the 10 control rats. Plasma and renal renin substrate were highly and positively correlated (r = 0.86; P less than 0.001). Inasmuch as plasma renin substrate is rate-limiting for angiotensin I, it may reflect intrarenal AII and prove to be a useful clinical assessment of converting enzyme inhibition. The increased levels of renin, renin substrate and packed cell volume seen in rats fed Purina basal diet (10% fat) as compared with rats fed Purina lab chow (4.5% fat), support the working hypothesis that intrarenal angiotensin II controls both blood pressure and erythropoiesis.

In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system

We examined angiotensinogen gene expression in rat kidney by in situ hybridization histochemistry. Using a rat cRNA probe to angiotensinogen, we demonstrated angiotensinogen mRNA to be localized predominantly in the proximal renal tubule, with considerably lesser amounts in distal tubular segments and glomerular tufts. Previous studies have localized renin immunoreactivity to the juxtaglomerular cells, glomerular tufts, and proximal tubules. Such findings provide further evidence for a local tissue renin angiotensin system within the kidney which may influence regional function. Based on our data, we hypothesize that a major site of angiotensin production is the proximal tubule. We postulate that angiotensin synthesized in and/or around the proximal tubule may directly modulate tubular transport of sodium, bicarbonate, and water. In addition to the proximal tubule, the specific localization of the renin angiotensin components elsewhere in the kidney would also support the other proposed regional functions of the intrarenal system, including modulation of tubuloglomerular balance.

Biochemistry and pharmacology of the renin-angiotensin system

Knowledge of the structure, function and distribution of the components of the renin-angiotensin-aldosterone system (RAS) and the integrated physiological role of this hormonal system is rapidly increasing, although many questions remain unanswered. The primary structure and localisation of RAS such as renin, prorenin, angiotensinogen, angiotensin-converting enzyme (ACE) and the angiotensins have now been described. Moreover, the genes for the production of renin and ACE have been cloned and their nucleotide sequences determined. In addition to its well-established role as a circulating endocrine system, the renin-angiotensin system has more recently been ascribed a local autocrine or paracrine function. Physiologically active levels of components such as renin and angiotensin, or their messenger RNAs, have been identified in several extrarenal tissues, notably the central nervous system. The components of such tissue renin-angiotensin systems may be derived from de novo tissue synthesis and/or from the circulation by endocytosis. Angiotensin has pharmacological actions on a wide range of body tissues, including the kidney, heart, brain, gastrointestinal tract and reproductive organs. In many of these locations, angiotensin receptors have been isolated and characterised. The most firmly established roles of angiotensin are the control of blood pressure and local blood flow, and in salt and water homeostasis; the physiological significance of many of angiotensin's tissue effects is unknown. In some areas of clinical interest, such as the pathophysiology of left ventricular hypertrophy, ACE inhibitors are very useful for elucidating the possible influences of the renin-angiotensin system.

The renin-angiotensin system: an overview of its intracellular function

The enzyme renin has been purified and characterized by structural analysis. Pure renin protein was used to produce a specific antibody to renin, which was useful in demonstrating the presence of a specific renin in many tissues other than kidney. Further, in these cells angiotensins I and II and converting enzyme all were found to coexist with renin by immunohistochemical studies, indicating the local production of renin, angiotensinogen and angiotensins in these cells. Angiotensin II produced in the cultured cells was secreted to the outside of the cells. Secretion of angiotensin II from the angiotensin-producing cells was demonstrated with perfused mesenteric artery. The secretion of angiotensin II from the vascular beds was inhibited by converting enzyme inhibitors, and was stimulated by the adrenergic beta-agonist isoproterenol. These studies demonstrate local production and controlled secretion of angiotensin II and define its physiologic role.

In vivo renal angiotensin converting enzyme activity decreases in glycerol-induced acute renal failure

We previously demonstrated that intrarenal angiotensin II generation during glycerol-induced acute renal failure was attenuated, which may have resulted from the inability of intrarenal converting enzyme to convert renal angiotensin I to angiotensin II. In order to test this hypothesis in vivo, we determined the ability of the kidney to convert angiotensin I to angiotensin II by measuring the decrease in renal cortical blood flow (RCBF) in response to exogenous angiotensin I administration. Changes in RCBF were monitored by laser-Doppler velocimetry. Three groups of rats were studied: Group I, controls (N = 7); 24 hours prior to study Group II animals were injected with 50% glycerol, 8 ml/kg i.m. (N = 4); and Group III rats were injected with mercuric chloride, 3 mg/kg s.c. (N = 5). All experimental animals had a three- to sixfold rise in serum creatinine. Mean glomerular filtration rate (GFR) of the left and right kidney in control rats was 0.7 and 0.7 ml/min, respectively. Twenty-four hours after glycerol, GFR was 0.2 ml/min in the left kidney and 0.2 ml/min in the right kidney. In HgCl2 treated rats GFR was 0.1 ml/min in the left kidney and 0.1 ml/min in the right kidney. Each of the following maneuvers elicited a similar rise in blood pressure in Groups I through III. Specifically, when first angiotensin I (4 micrograms/kg/min) was infused for three minutes; second, when 10 minutes later angiotensin I (5 micrograms) was directly applied on the left kidney; and third, when angiotensin II (5 micrograms) was topically administered.(ABSTRACT TRUNCATED AT 250 WORDS)

Direct release of angiotensins I and II from isolated rat kidney perfused with angiotensinogen-free medium

A direct measurement of both angiotensins I and II immunoreactive substances was made in the perfusate from isolated rat kidney perfused with Krebs-Ringer solution which was free of any component of the renin-angiotensin system. The identity of the immunoreactive peptides was confirmed as angiotensin I and angiotensin II by high-pressure liquid chromatography in reference to standard compounds. The rate of release of angiotensins was as high as 1313.5 +/- 184.5 and 772.4 +/- 82.5 pg for angiotensins I and II, respectively, during the first perfusion period of 20 min, and it remained stable at least for 2 hours. There was a good relationship between the angiotensin I secretion rate and renin secretion rate simultaneously determined in the perfusate, and also between the angiotensin I secretion rate and angiotensin II secretion rate. These results taken together with the previous observations of the coexistence of renin and angiotensins I and II in juxtaglomerular cells of the kidney provide evidence for intrarenal formation and release of angiotensin II. It does not agree with the notion that these peptides are internalized from circulation. Angiotensin II secreted from the kidney may play diverse functions in intrarenal regulation.

Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla

Rat liver angiotensinogen cDNA (pRang 3) and mouse renin cDNA (pDD-1D2) were used to identify angiotensinogen and renin mRNA sequences in rat kidney cortex and medulla in rats on high and low salt diet. Angiotensinogen mRNA sequences were present in renal cortex and medulla in apparently equal proportions, whereas renin mRNA sequences were found primarily in renal cortex. Average relative signal of rat liver to whole kidney angiotensinogen mRNA was 100:3. Densitometric analysis of Northern blots demonstrated that renal cortical angiotensinogen mRNA concentrations increased 3.5-fold (P less than 0.001) and medulla, 1.5-fold (P less than 0.005) on low sodium compared with high sodium diet, whereas renal cortex renin mRNA levels increased 6.8-fold (P less than 0.0005). Dietary sodium did not significantly influence liver angiotensinogen mRNA levels. These findings provide evidence for sodium regulation of renal renin and angiotensinogen mRNA expressions, which supports potential existence of an intrarenally regulated RAS and suggest that different factors regulate renal and hepatic angiotensinogen.

Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat

To define the role of local synthesis of angiotensinogen in tissue angiotensin production, we have quantitated angiotensinogen messenger RNA (mRNA) levels in 17 different tissues of four groups of rats: control rats, nephrectomized rats, rats given dexamethasone, ethynylestradiol, and triiodothyronine, and nephrectomized rats given dexamethasone, ethynylestradiol, and triiodothyronine. Angiotensinogen mRNA was identified in 12 tissues: liver, kidney, brain, spinal cord, aorta, mesentery, atria, lung, adrenal, large intestine, stomach, and spleen. Angiotensinogen mRNA was not identified in pituitary, ventricle, testis, small intestine, or pancreas. When expressed per gram tissue wet weight, angiotensinogen mRNA levels of extrahepatic tissues were less than 4% of hepatic levels. However, when expressed per milligram total RNA, angiotensinogen mRNA levels of brain, spinal cord, aorta, and mesentery were 26-42% of hepatic levels. Regulation of angiotensinogen mRNA levels was tissue specific. This demonstration of a widespread tissue distribution of angiotensinogen mRNA may indicate a similarly widespread distribution of local angiotensin systems that are independent of the circulating renin-angiotensin system.

Evidence for existence of angiotensins I and II in mature renin granules from rat kidney cortex

Renin granules were isolated by the combination of discontinuous and continuous Percoll density gradient centrifugation. The peak fraction containing the highest concentration of renin granules was found to contain the highest concentration of both angiotensin I and II immunoreactive substances. The identity of the immunoreactive peptides was further confirmed as angiotensin I and angiotensin II by high pressure liquid chromatography in reference to standard compounds. The coexistence of angiotensins I and II with renin indicates the formation of angiotensin II in renin granules. These findings clarify the mechanism of intracellular formation of angiotensin II as opposed to its formation in plasma and provide evidence against the internalization of angiotensin II, a hypothesis supported by the failure to detect angiotensin I in renin granules. Angiotensin II was increased by a low sodium diet while a high sodium diet did not affect its content.

Ultrastructural immunocytochemical localization of renin and angiotensin II in the juxtaglomerular cells of the ischemic kidney in experimental renal hypertension

Partial ligation of the rat aorta between the renal arteries induces acute hypertension with atrophy of the left (ischemic) kidney, intense stimulation of juxtaglomerular cell (JGC) secretory activity, and significant increases in renal cortical renin activity, in plasma renin activity, and in the plasma levels of angiotensin I (AI) and angiotensin II (AII). With the unlabeled antibody technique at the light-microscopic level and various dilutions of renin antiserum, immunoreactive renin can be visualized in the JGC of sham-operated controls with high dilutions of antiserum that do not reveal renin in the JGC of ischemic kidney. The reverse is true with AII antisera; ie, high dilutions of AII antisera immunostain the JGCs of ischemic kidney but not those of control kidney. With the protein A-gold technique at the electron-microscopic level, using gold particles of small and large size and immunoreacting the two faces of a fine section, renin and AII can be localized in the same JGC secretory granules. With the same technique (immunoreacting only one face of a fine section with small gold particles), quantitative analysis reveals a lower concentration of renin and a higher concentration of AII in the secretory granules of the ischemic kidney JGCs; these granules are also of smaller size than those of control kidney JGCs. AI cannot be visualized in these cells at either the light- or electron-microscopic level. These results indicate that AII co-localized with renin in JGC secretory granules and probably co-secreted, is not synthetized by these cells but is internalized following receptor binding.

Immunocytochemical localization of angiotensinogen in rat liver and kidney

The renin substrate, angiotensinogen, was localized by immunocytochemistry in liver and kidney of normal rats by the use of an antiserum directed against pure rat angiotensinogen. This substrate was also examined in rats after bilateral nephrectomy, which is known to increase plasma angiotensinogen, and in rats treated with colchicine, which inhibits serum protein secretion. In normal rat liver, light microscopy showed the presence of immunoreactive material in a very few cells. The number of stained hepatocytes rose in rats treated with colchicine or after bilateral nephrectomy. Immuno-staining increased further when rats were both nephrectomized and colchicine treated. In the kidney, angiotensinogen was specifically located as granular formations in nephrocytes of the proximal tubule but never in the granular cells of the juxtaglomerular apparatus. The localization of these granular formations under the brush border suggests that angiotensinogen is reabsorbed from the glomerular ultrafiltrate rather than synthesized in the kidney.

Local generation of angiotensin in the kidney and in tissue culture

The renin-angiotensin system is an exception among the various peptide hormone producing mechanisms in that it is an extracellular system. It was not clear whether renin in tissues other than kidney participates in the extracellular system or an intracellular mechanism. We examined the possibility of intracellular formation of angiotensin II in these tissues by using cloned, renin containing cells in culture as models. Neuroblastoma cells, pheochromocytoma cells, adrenal cortical cells and juxtaglomerular cells were shown to contain renin, angiotensin I and angiotensin II. Presence of angiotensin I converting enzyme was also demonstrated in some cell lines examined. Even juxtaglomerular cells in the intact kidney were shown to contain angiotensin I and angiotensin II by immunohistochemical technique. These findings indicate an intracellular mechanism of angiotensin II formation in various tissues and suggest that angiotensin II may have local paracrine functions.

Measurement and localization of angiotensin-like immunoreactivity in juxtaglomerular cells of the rat

The existence and distribution of angiotensin I (A I) and angiotensin II (A II) in rat kidney were examined in immunocytochemical studies using the peroxidase-antiperoxidase technique and in biochemical studies using rat kidney homogenates extracted with acid-ethanol and purified by Sephadex G-25 gel chromatography. Immunopositive A II-like staining was observed in the juxtaglomerular cells of the afferent arteriole, but no histochemical evidence for A I was found. On the other hand, renal homogenates were found to contain both A I and A II immunoreactivities which coeluted on gel chromatography with synthetic A I and A II. These results indicate that A I as well as A II immunoreactivities are present in the kidney and that A II immunoreactivity can be localized to the juxtaglomerular cells. The origin of the immunoreactive A II in the juxtaglomerular cells remains to be determined.

Hypotensive action of captopril and saralasin in intact and anephric spontaneously hypertensive rats

Intravenous injection of the converting enzyme inhibitor SQ14,225 (captopril, 2 mg/kg) reduced the blood pressure of anesthetized, spontaneously hypertensive rats (SHR) progressively over a 3-hour period. An indistinguishable fall in blood pressure occurred in SHR that were bilaterally nephrectomized 1 hour prior to injection of the converting enzyme inhibitor. In the nephrectomized animals, plasma renin activity (PRA) had fallen to less than 30% of its initial values at the time of injection. Injection of the vehicle alone had no effect on blood pressure in either anephric or intact SHR. The converting enzyme inhibitor produced no significant change in the blood pressure of either intact or anephric normotensive Wistar-Kyoto (NT-WK) rats. Infusions of Sar1-Ala8-angiotensin II (saralasin, 10 micrograms/kg-1/min-1) similarly reduced blood pressure of both intact and anephric SHR. These results indicate that captopril and saralasin lower blood pressure in the SHR by some mechanism(s) independent of the kidneys, circulating renin, or bradykinin potentiation. It is suggested that angiotensin II, locally produced at some critical tissue site(s), is involved in the maintenance of raised blood pressure in SHR.

Partial purification of dog angiotensinogen

Dog angiotensinogen was purified 450-fold from the plasma of nephrectomized dogs by a simple four-step procedure involving precipitation between 1.5 and 2.3 M ammonium sulfate, gel filtration on Sephadex G-150, ion-exchange chromatography on DE-52 cellulose, and affinity chromatography on Concanavalin A-Sepharose. The purity of the final preparation was over 50%. The preparation of dog angiotensinogen had an apparent molecular weight of 80,000 determined by gel filtration on Sephadex G-100. Kinetic studies indicated that the Km of the reaction of dog renin with partially purified dog angiotensinogen (1,840 pmol/ml) was similar to that for the reaction with angiotensinogen in diluted dog plasma (1,820 pmol/ml). Thus the purification procedures employed did not alter the affinity of dog renin for the Leu10-Leu11 bond of dog angiotensinogen. Because the concentration of angiotensinogen in dog plasma is about 700 pmol/ml, a first order reaction with respect to substrate is indicated in vivo.

Feedback regulation of nephron filtration rate during pharmacologic interference with the renin-angiotensin and adrenergic systems in rats

Tubuloglomerular feedback has been defined as a mechanism in which changes in distal tubular sodium chloride delivery induce changes in glomerular arteriolar resistance. Experiments were performed in rats to test the hypothesis that the alterations in vasomotor activity are controlled by local hormonal mechanisms. Early proximal flow rate (EPFR), used as an index of filtration rate, was assessed at loop perfusion rates of 10 and 40 nl/min and during zero loop flow before and during intravenous administration of agents which interfere with the reninangiotensin or adrenergic systems. During infusion of the angiotensin (A) antagonists [Sar1,Ile8-]-AII or [Me2,Gly1,Ile8]-AII at doses ranging from 4.8 to 30.6 micrograms/kg . min, feedback response, expressed as percent change of EPFR during loop flow elevation from 3 to 40 nl/min, fell from a mean of 47.6 +/- 3.3% to 33.2 +/- 2.9% (P less than 0.05). Likewise, after administration of the converting enzyme inhibitor SQ 20881 in a dose ranging between 5.5 and 34.0 mg/kg, feedback response decreased from 48.5 +/- 2.1% to 25.9 +/- 1.9% (P less than 0.001) and returned to 43.1 +/- 5.1% after the inhibitory effect of SQ 20881 on the pressure response to angiotensin I had disappeared. Luminal application of [Sar1,Thr2]-AII (5mM) or of SQ 20881 (5 or 10 mM) had no effect on the feedback response. A significant reduction in the feedback response was noted also during intravenous infusion of propranolol (46.4 +/- 3.2% vs. 29.0 +/- 2.8%, P less than 0.001), whereas 6-OH-dopamine, reserpine, or phenoxybenzamine had no detectable effect. Our results are in agreement with the concept that the renin-angiotensin system may mediate feedback-induced resistance changes. In addition, circulating catecholamines may, in some unknown manner, act as modulators of the feedback response.

Properties of the activation by pepsin of inactive renin in human amniotic fluid

1. The renin present in human amniotic fluid was found to have an apparent Mr of 58 000 by gel filtration and is thus bigger than renin in untreated kidney extracts and plasma (Mr approximately 40 000). 2. Treatment with pepsin (40 microgram/ml pH 4.8, 2 h, 22 degrees C) caused a 6-fold increase in activity of this renin species, although Mr was not very different (57 000). 3. Unlike renal renin, renin in human amniotic fluid was not a glycoprotein and behaved similarly on concanavalin A-Sepharose before and after activation by pepsin. 4. Ion-exchange chromatography demonstrated a small change in the ionization properties of human amniotic fluid renin after activation by pepsin. 5. Pepsin-mediated activation resulted in a five-fold increase in V, but only a small decrease in the Km of renin to 39% of normal, so that the increase in activity observed was not due to an increase in the affinity of the enzyme for its substrate. The kinetic data were consistent with the theory of noncompetitive inhibition. 6. The activation of human amniotic fluid renin by pepsin may be caused by a change in the tertiary structure of the molecule subsequent to a proteolytic action that does not remove detectable polypeptide components.

Mechanism of interference by chelating agents and sucrose in radioimmunoassay of angiotensin I

EDTA, 2,3-dimercaptopropanol and sucrose were shown by Scatchard analysis to interfere in the radioimmunoassay of angiotensin I by altering the affinity, but not the capacity, of antibody for antigen. It is stressed that when interfering reagents are present in samples the assay result must be obtained from a standard curve in which each standard contains the interfering reagent(s) at a similar concentration as present in each sample mixture.